Egidio Spinelli1, Kyle R Christensen2, Emily Bryant3,4, Amy Schneider5, Jennifer Rakotomamonjy6, Alison M Muir7, Jessica Giannelli3, Rebecca O Littlejohn8,9, Elizabeth R Roeder8,9, Berkley Schmidt10, William G Wilson10, Elysa J Marco11,12, Kazuhiro Iwama13, Satoko Kumada14, Tiziana Pisano15, Carmen Barba15, Annalisa Vetro15, Eva H Brilstra16, Richard H van Jaarsveld16, Naomichi Matsumoto13, Hadassa Goldberg-Stern17, Patrick W Carney18, P Ian Andrews19, Christelle M El Achkar17, Sam Berkovic5, Lance H Rodan20, Kirsty McWalter21, Renzo Guerrini15, Ingrid E Scheffer5, Heather C Mefford7, Simone Mandelstam22,23, Linda Laux3,24, John J Millichap3,24, Alicia Guemez-Gamboa6, Angus C Nairn2, Gemma L Carvill24,25,26. 1. Schulich School of Medicine and Dentistry, Western University, London, ON, Canada. 2. Department of Psychiatry, Yale School of Medicine, Connecticut Mental Health Center, New Haven, CT. 3. Epilepsy Center and Division of Neurology, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL. 4. Division of Genetics, Birth Defects and Metabolism, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL. 5. Epilepsy Research Centre, Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, VIC, Australia. 6. Department of Physiology, Northwestern University Feinberg School of Medicine, Chicago, IL. 7. Division of Genetic Medicine, Department of Pediatrics, University of Washington, Seattle, WA. 8. Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX. 9. Department of Pediatrics, Baylor College of Medicine, San Antonio, TX. 10. Division of Medical Genetics, University of Virginia, Charlottesville, VA. 11. Department of Pediatrics, University of California, San Francisco, CA. 12. Research Division, Cortica Healthcare, San Rafael, CA. 13. Department of Human Genetics, Yokohama City University Graduate School of Medicine, Yokohama, Japan. 14. Department of Neuropediatrics, Tokyo Metropolitan Neurological Hospital, Tokyo, Japan. 15. Neuroscience Department, Children's Hospital A. Meyer-University of Florence, Florence, Italy. 16. Genetics Department, University Medical Centre Utrecht, Utrecht, The Netherlands. 17. Epilepsy Unit and EEG Lab, Schneider Medical Center, Petah Tikv, Israel. 18. Eastern Health Clinical School, Monash University, Melbourne, Victoria, Australia. 19. Department of Neurology, Sydney Children's Hospital, Sydney, New South Wales, Australia. 20. Department of Neurology and Division of Genetics and Genomics, Boston Children's Hospital, Boston, MA. 21. GeneDx, Gaithersburg, MD. 22. Department of Pediatrics and Radiology, University of Melbourne, Melbourne, VIC, Australia. 23. Department of Medical Imaging, Royal Children's Hospital of Melbourne, Melbourne, VIC, Australia. 24. Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL. 25. Ken and Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL. 26. Department of Pharmacology, Northwestern University Feinberg School of Medicine, Chicago, IL.
Abstract
OBJECTIVE: The MAST family of microtubule-associated serine-threonine kinases (STKs) have distinct expression patterns in the developing and mature human and mouse brain. To date, only MAST1 has been conclusively associated with neurological disease, with de novo variants in individuals with a neurodevelopmental disorder, including a mega corpus callosum. METHODS: Using exome sequencing, we identify MAST3 missense variants in individuals with epilepsy. We also assess the effect of these variants on the ability of MAST3 to phosphorylate the target gene product ARPP-16 in HEK293T cells. RESULTS: We identify de novo missense variants in the STK domain in 11 individuals, including 2 recurrent variants p.G510S (n = 5) and p.G515S (n = 3). All 11 individuals had developmental and epileptic encephalopathy, with 8 having normal development prior to seizure onset at <2 years of age. All patients developed multiple seizure types, 9 of 11 patients had seizures triggered by fever and 9 of 11 patients had drug-resistant seizures. In vitro analysis of HEK293T cells transfected with MAST3 cDNA carrying a subset of these patient-specific missense variants demonstrated variable but generally lower expression, with concomitant increased phosphorylation of the MAST3 target, ARPP-16, compared to wild-type. These findings suggest the patient-specific variants may confer MAST3 gain-of-function. Moreover, single-nuclei RNA sequencing and immunohistochemistry shows that MAST3 expression is restricted to excitatory neurons in the cortex late in prenatal development and postnatally. INTERPRETATION: In summary, we describe MAST3 as a novel epilepsy-associated gene with a potential gain-of-function pathogenic mechanism that may be primarily restricted to excitatory neurons in the cortex. ANN NEUROL 2021;90:274-284.
OBJECTIVE: The MAST family of microtubule-associated serine-threonine kinases (STKs) have distinct expression patterns in the developing and mature human and mouse brain. To date, only MAST1 has been conclusively associated with neurological disease, with de novo variants in individuals with a neurodevelopmental disorder, including a mega corpus callosum. METHODS: Using exome sequencing, we identify MAST3 missense variants in individuals with epilepsy. We also assess the effect of these variants on the ability of MAST3 to phosphorylate the target gene product ARPP-16 in HEK293T cells. RESULTS: We identify de novo missense variants in the STK domain in 11 individuals, including 2 recurrent variants p.G510S (n = 5) and p.G515S (n = 3). All 11 individuals had developmental and epileptic encephalopathy, with 8 having normal development prior to seizure onset at <2 years of age. All patients developed multiple seizure types, 9 of 11 patients had seizures triggered by fever and 9 of 11 patients had drug-resistant seizures. In vitro analysis of HEK293T cells transfected with MAST3 cDNA carrying a subset of these patient-specific missense variants demonstrated variable but generally lower expression, with concomitant increased phosphorylation of the MAST3 target, ARPP-16, compared to wild-type. These findings suggest the patient-specific variants may confer MAST3 gain-of-function. Moreover, single-nuclei RNA sequencing and immunohistochemistry shows that MAST3 expression is restricted to excitatory neurons in the cortex late in prenatal development and postnatally. INTERPRETATION: In summary, we describe MAST3 as a novel epilepsy-associated gene with a potential gain-of-function pathogenic mechanism that may be primarily restricted to excitatory neurons in the cortex. ANN NEUROL 2021;90:274-284.
Authors: Ingrid E Scheffer; Samuel Berkovic; Giuseppe Capovilla; Mary B Connolly; Jacqueline French; Laura Guilhoto; Edouard Hirsch; Satish Jain; Gary W Mathern; Solomon L Moshé; Douglas R Nordli; Emilio Perucca; Torbjörn Tomson; Samuel Wiebe; Yue-Hua Zhang; Sameer M Zuberi Journal: Epilepsia Date: 2017-03-08 Impact factor: 5.864
Authors: Erika C Andrade; Veronica Musante; Atsuko Horiuchi; Hideo Matsuzaki; A Harrison Brody; Terence Wu; Paul Greengard; Jane R Taylor; Angus C Nairn Journal: J Neurosci Date: 2017-02-06 Impact factor: 6.167
Authors: Candace T Myers; Georgina Hollingsworth; Alison M Muir; Amy L Schneider; Zoe Thuesmunn; Allison Knupp; Chontelle King; Amy Lacroix; Michele G Mehaffey; Samuel F Berkovic; Gemma L Carvill; Lynette G Sadleir; Ingrid E Scheffer; Heather C Mefford Journal: N Engl J Med Date: 2018-04-26 Impact factor: 91.245
Authors: William P Gilks; Patrick M Abou-Sleiman; Sonia Gandhi; Shushant Jain; Andrew Singleton; Andrew J Lees; Karen Shaw; Kailash P Bhatia; Vincenzo Bonifati; Niall P Quinn; John Lynch; Daniel G Healy; Janice L Holton; Tamas Revesz; Nicholas W Wood Journal: Lancet Date: 2005 Jan 29-Feb 4 Impact factor: 79.321
Authors: Tangpo Yang; Adolfo Cuesta; Xiaobo Wan; Gregory B Craven; Brad Hirakawa; Penney Khamphavong; Jeffrey R May; John C Kath; John D Lapek; Sherry Niessen; Alma L Burlingame; Jordan D Carelli; Jack Taunton Journal: Nat Chem Biol Date: 2022-05-19 Impact factor: 16.174